VEGFR-2 蛋白, Human (HEK293, His)

VEGFR-2 is a tyrosine-protein kinase of the cell surface receptors of VEGFA, VEGFC, and VEGFD that mediates activation of the MAPK1/ERK2, MAPK3/ERK1, and MAP kinase signaling pathways, as well as the AKT1 signaling pathway. VEGFR-2 can promote the proliferation, survival, migration and differentiation of endothelial cells. Overexpression of VEGFR-2 is associated with the development of tumors. VEGFR-2 Protein, Human (HEK293, His) is the recombinant human-derived VEGFR-2 protein, expressed by HEK293 , with C-His labeled tag. The total length of VEGFR-2 Protein, Human (HEK293, His) is 745 a.a., with molecular weight of 84-140 kDa.

VEGF 受体 (VEGFRs) 是血管内皮生长因子 (VEGF) 的受体，主要有三种亚型，VEGFR-1,、VEGFR-2 和VEGFR-3。VEGFR-2 可作为 VEGFA, VEGFC 和 VEGFD 的细胞表面受体的酪氨酸蛋白激酶，在血管生成、血管发育、血管通透性和胚胎造血中起重要作用。可促进内皮细胞的增殖、存活、迁移和分化。促进肌动蛋白细胞骨架的重组。VEGFR-2 通过形成异源二聚体调节VEGFR-1 (FLT1) 和 VEGFR-3 (FLT40) 信号。VEGFR-2 可介导 MAPK1/ERK2、MAPK3/ERK1 和 MAP 激酶信号通路以及 AKT1 信号通路的激活。介导磷脂酰肌醇 3-激酶调控亚基 PIK3R1 的磷酸化、肌动蛋白细胞骨架的重组和 PTK2/FAK1 的激活。VEGFA 介导的 NOS2 和 NOS3 的诱导是必需的，导致内皮细胞产生信号分子一氧化氮 (NO)。磷酸化 PLCG1 。促进 FYN、NCK1、NOS3、PIK3R1、PTK2/FAK1 和 SRC 的磷酸化。VEGFR-2 的过表达与肿瘤的发生有关。

Measured by its ability to inhibit the VEGF-dependent proliferation of HUVEC human umbilical vein endothelial cells. The ED₅₀for this effect is 9-160 ng/mL in the presence of 10 ng/mL recombinant human VEGF165.

• 
  Measured by its ability to inhibit the VEGF-dependent proliferation of HUVEC human umbilical vein endothelial cells. The ED₅₀ for this effect is 9.805 ng/mL in the presence of 10 ng/mL recombinant human VEGF165, corresponding to a specific activity is 1.020×10⁵ units/mg.

Human

HEK293

C-His

AAI31823.1 (A20-E764)

3791  [NCBI]

ASVGLPSVSLDLPRLSIQKDILTIKANTTLQITCRGQRDLDWLWPNNQSGSEQRVEVTECSDGLFCKTLTIPKVIGNDTGAYKCFYRETDLASVIYVYVQDYRSPFIASVSDQHGVVYITENKNKTVVIPCLGSISNLNVSLCARYPEKRFVPDGNRISWDSKKGFTIPSYMISYAGMVFCEAKINDESYQSIMYIVVVVGYRIYDVVLSPSHGIELSVGEKLVLNCTARTELNVGIDFNWEYPSSKHQHKKLVNRDLKTQSGSEMKKFLSTLTIDGITRSDQGLYTCAASSGLMTKKNSTFVRVHEKPFVAFGSGMESLVEATVGERVRIPAKYLGYPPPEIKWYKNGIPLESNHTIKAGHVLTIMEVSERDTGNYTVILTNPISKEKQSHVVSLVVYVPPQIGEKSLISPVDSYQYGTTQTLTCTVYAIPPPHHIHWYWQLEEECANEPSHAVSVTNPYPCEEWRSVEDFQGGNKIEVNKNQFALIEGKNKTVSTLVIQAANVSALYKCEAVNKVGRGERVISFHVTRGPEITLQPDMQPTEQESVSLWCTADRSTFENLTWYKLGPQPLPIHVGELPTPVCKNLDTLWKLNATMFSNSTNDILIMELKNASLQDQGDYVCLAQDRKTKKRHCVVRQLTVLERVAPTITGNLENQTTSIGESIEVSCTASGNPPPQIMWFKDNETLVEDSGIVLKDGNRNLTIRRVRKEDEGLYTCQACSVLGCAKVEAFFIIEGAQEKTNLE

84-140 kDa

• 
  Greater than 95% as determined by reducing SDS-PAGE.

无菌粉末

Lyophilized from a 0.2 μm filtered solution of PBS, pH 7.4 or 20 mM PB, 150 mM NaCl, pH 7.4.

<1 EU/μg, determined by LAL method.

It is not recommended to reconstitute to a concentration less than 100 μg/mL in ddH₂O. For long term storage it is recommended to add a carrier protein (0.1% BSA, 5% HSA, 10% FBS or 5% Trehalose).

Stored at -20°C for 2 years. After reconstitution, it is stable at 4°C for 1 week or -20°C for longer (with carrier protein). It is recommended to freeze aliquots at -20°C or -80°C for extended storage.

Room temperature in continental US; may vary elsewhere.